Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:18:14 EDT Mon 14 Sep 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

News last 24 hour(s) - 16 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2026-09-14 01:00U:VSATNews ReleaseSpace42 and Viasat Sign Binding Agreement to co-found Equatys, Creating the First Shared Space and Ground Infrastructure Platform for Global Direct-to-Device and Advanced MSS Connectivity
2026-09-14 00:16U:SLVRFNews ReleaseSilver One Commences Microgravity Survey at the Phoenix Silver's 417 High-Grade Silver Target to Test for Potential Dense Metallic Bodies
2026-09-13 21:55U:AZNNews ReleaseENHERTU(TM) (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
2026-09-13 21:47U:AZNNews ReleaseTAGRISSO(TM) (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial
2026-09-13 21:45U:JNJNews ReleaseJohnson & Johnson's RYBREVANT(TM) (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
2026-09-13 21:30U:WHWKNews ReleaseWhitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026
2026-09-13 20:38U:FNVNews ReleaseFranco-Nevada Announces A$200 Million Follow-on Financing Package with Minerals 260 for the Bullabulling Gold Project
2026-09-13 20:38U:FNVNews ReleaseFranco-Nevada Announces A$200 Million Follow-on Financing Package with Minerals 260 for the Bullabulling Gold Project
2026-09-13 19:38U:TMKEFNews ReleaseTMK Energy Ltd (TMKEF) Gas Production Milestone Achieved
2026-09-13 19:15U:CGEMNews ReleaseZipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
2026-09-13 19:00U:FFAINews ReleaseFaraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: Previews the Upcoming 9/19 Event; Highlights FF's EAI Robotics' Autonomous Perception and 3D Scanning Technology; Adds a New Senior Advisor Focused on Govt. Procurement
2026-09-13 19:00U:BKRNews ReleaseBaker Hughes and Venture Global Advance Next Phase of U.S. Gas Infrastructure Growth
2026-09-13 18:56U:RMXFFNews ReleaseRed Mountain Mining Limited (RMXFF) Further Strong Tungsten and Copper Assays at Pioneer Project
2026-09-13 18:56U:ALMNews ReleaseRed Mountain Mining Limited (RMXFF) Further Strong Tungsten and Copper Assays at Pioneer Project
2026-09-13 17:00U:DFTXNews ReleaseDefinium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026
2026-09-13 07:00U:SMMTNews ReleaseIvonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Conducted in China